Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 10/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806367 | 1.00 | CACNA1G (0.45) | CACNA1GCACNA1HCACNA1IBRD4SIRT1 | |
| SCHEMBL1806370 | 1.00 | CACNA1G (0.45) | CACNA1GCACNA1HCACNA1IBRD4SIRT1 | |
| SCHEMBL1805149 | 0.80 | HTR2A (0.40) | TRPV1HTR2AHTR2C | |
| SCHEMBL1805150 | 0.80 | HTR2A (0.40) | TRPV1HTR2AHTR2C | |
| SCHEMBL1805148 | 0.80 | HTR2A (0.40) | TRPV1HTR2AHTR2C | |
| SCHEMBL1809209 | 0.78 | NOTUM (0.49) | BRD4 | |
| SCHEMBL1809206 | 0.78 | NOTUM (0.49) | BRD4 | |
| SCHEMBL1809207 | 0.78 | NOTUM (0.49) | BRD4 | |
| SCHEMBL5705179 | 0.76 | SIRT2 (0.51) | SIRT1 | |
| SCHEMBL5705178 | 0.76 | SIRT2 (0.51) | SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CACNA1G 1780/4885CACNA1H 1323/4885CACNA1I 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.